Paloma Pharmaceuticals employs a virtual model for drug development, using a small in-house workforce to reduce cash burn and to outsource all work to specialized contract research and development groups, economizing on the expense of maintaining in-house specialized teams. This also allows for flexibility and limited down-time to train expert drug development teams.
David Sherris, Ph.D.
President and Chief Executive Officer
Dr. Sherris has over 25 years of experience in the biopharmaceutical and diagnostics world. Most recently, Dr. Sherris was the chief executive and founder of Sherris Pharma Partners, a consulting/out-sourcing company providing business development and R&D help with a niche focus in angiogenesis and vascular targeting. In addition, Dr. Sherris has worked with venture capital companies where he has both advised and raised seed money for biotech startups. Prior to his starting Sherris Pharma Partners, Dr. Sherris had been employed by pharmaceutical and biotechnology companies to manage external R&D (academic groups and contract research organizations) to augment and expand internal scientific programs. Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical business and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas. Dr. Sherris has held positions at Centocor, Unilever Research, Serono and OXiGENE where he was Chief Operating Officer and Vice President of Research and Development, as well as Chief Operating Officer of a joint venture between OXiGENE and Peregrine Pharmaceuticals, Arcus LLC. Dr. Sherris received his Ph.D. in Biochemistry from the University of Utah, held a postdoctoral position in immunology at the Jackson Laboratory and a faculty position in the Department of Medicine, Division of Clinical Immunology at the Mt. Sinai Medical Center, New York, NY.
James N. Little, Ph.D.
Dr. Little is currently CEO and President of i2Chem, Inc. a startup company focused in the area of continuous flow reaction technology. From 1998 to 2006, Mr. Little served as Senior Vice President at Cetek Corporation, a drug discovery company based in Marlborough, MA. Mr. Little holds an undergraduate degree in Chemistry from University of Kansas and a Ph. D. in Analytical Chemistry from Massachusetts Institute of Technology.
John M. Sorvillo, Ph.D.
Dr. Sorvillo is currently Vice President of Business Development at Genocea Biosciences. Dr. Sorvillo joined Genocea from Altus Pharmaceuticals, where he led all partnering activities as Vice President of Business Development since his appointment in 2006. Before joining Altus, Dr. Sorvillo served as Chief Executive Officer of Bionaut Pharmaceuticals. From 1995 to 2005, Dr. Sorvillo acted as Vice President of Business Development at ArQule, where he played key roles in establishing many technology and product collaborations with pharmaceutical companies, including a $345 million strategic alliance with Pfizer. Prior to ArQule, Dr. Sorvillo held a variety of positions at OSI Pharmaceuticals leading up to his last position as Vice President and General Manager, Research Products Division. Dr. Sorvillo was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and received his Ph.D. in Immunology from the New York University Medical Center, Sackler Institute of Biomedical Sciences. He holds a B.A. in Biology from the City University of New York, Hunter College. Dr. Sorvillo is a senior executive with a demonstrated success in business development possessing technical competency and the ability to create shareholder value. Dr. Sorvillo has over twenty two years of experience and significant achievements in the biotechnology industry in the successful commercialization of preclinical and clinical pharmaceutical programs, discovery technologies, diagnostic and research products.
The following individuals constitute the Company's Advisory Board by lending their expertise and industry experience.
Louis J. Kates, CPA
Tax and Accounting
Starr, Finer, Starr LLP
James H. Belanger, J.D.
Legal Affairs, Business Development
Burns & Levinson LLP
Mr. Belanger is a partner in the Boston law firm of Burns & Levinson, LLP, where he is a member of the Corporate and Intellectual Property departments and a co-chair of the Life Sciences Group. Mr. Belanger practices corporate and technology law, and works extensively with emerging technology companies. Mr. Belanger is a member of the Massachusetts bar and the Association of University Technology Managers. He received his J.D. degree from Boston College Law School, magna cum laude, in 1972, where was the Assistant Editor-in-Chief of the Law Review and a member of the Order of the Coif, a national legal honor society. He received his A.B. from the University of Notre Dame in 1965.
Ralph DeMartino, J.D.
F. Alec Orudjev, J.D.
Corporate and Securities Counsel
Jay S. Duker, M.D.
Tufts New England Medical Center
Dr. Duker is Professor and Chair of Ophthalmology, Tufts University School of Medicine, Director of the New England Eye Center, Vitreoretinal Diseases & Surgery Service and Director of the Pediatric Retinal Referral Center, Uveitis & Immunology Service. Dr. Duker specializes in both medical and surgical diseases of the posterior segment. His primary surgical interests include retinal detachment, proliferative vitreoretinopathy, proliferative diabetic retinopathy, retinopathy of prematurity, and posterior segment trauma with additional focus on posterior segment uveitis, AIDS-related retinitis, intraocular tumors, and retinal vascular disorders. Dr. Duker pioneered clinical use and ran clinical trials for gangcyclovir implant, one of the first implants used in ocular medicine.
Jason Slakter, M.D.
Vitreous-Retina-Macula Consultants of New York
Dr. Slakter's expertise in macular disease diagnostics is extensive. He has played a leading role and is widely published in the development of digital indocyanine green angiography (ICG) for the evaluation and management of macular degeneration and chorioretinal inflammatory disease. He created and is the director of the digital Angiography Reading Center, which serves as a key resource for numerous industry sponsored studies. He has served as a Principal Investigator in the clinical trials for photodynamic therapy for the treatment of wed AMD and is currently conducting clinical studies for the treatment of central serous chorioretinopathy. Dr. Slakter is a member of numerous medical organizations including the Macular and Retina Societies, and the American Society of Retinal Specialists. He is the Editor-in-Chief of Retinal Physician, is on the editorial board of Retina and serves as a scientific review or major scientific ophthalmic journals. He is the recipient of a number of awards including the American Academy of Ophthalmology Honor Award, the Macula Society's Richard and Hinda Rosenthal Award, and the Helen Keller Manhattan League Award.
Jeffery Heier, M.D.
Ophthalmic Consultants of Boston
Dr. Heier is a Vitreoretinal Specialist at Ophthalmic Consultants of Boston, Co-Director of the Vitreoretinal Fellowship at OCB/Tufts Medical School, and President of the Center for Eye Research and Education in Boston, Massachusetts. Dr. Heier is an Assistant Professor at Tufts University School of Medicine and a Clinical Instructor at Harvard University Medical School. Dr. Heier received a medical degree from Boston University School of Medicine in Massachusetts, and subsequently completed a transitional internship and ophthalmic residency at Fitzsimons Army Medical Center. Dr. Heier completed a vitreoretinal fellowship at Ophthalmic Consultants of Boston/Tufts University School of Medicine. Dr. Heier's research interests are focused on age-related macular degeneration (ARMD), diabetic retinopathy, and innovation in vitreoretinal surgical instrumentation. Dr. Heier lectures nationally and internationally regarding innovative treatments of devastating eye diseases such as macular degeneration and diabetic retinopathy.
Lee Rosen, M.D.
Lee S. Rosen, MD President and Founder of Premier Oncology is a principal investigator for many clinical trials focusing on new cancer drug development (Phase I), particularly in the treatment of gastrointestinal malignancies. Formerly Assistant Professor in the Division of Hematology-Oncology, Department of Medicine at the University of California, Los Angeles, where he founded the Cancer Therapy Development Program, Dr. Rosen has made significant contributions to translational research with angiogenesis inhibitors, signal transduction inhibitors and new drug combinations. His work with angiogenesis inhibitors goes back to 1996 and he has since treated hundreds of patients with more than a dozen drugs in this class. In 2004, Lee S. Rosen, M.D. created Premiere Oncology to continue the research he began in 1996 as founder of the Developmental Therapeutics Program at the University of California, Los Angeles (UCLA). The program was created following completion of his fellowship and was designed to conduct early stage (Phase I and Phase II) clinical trials of novel therapeutics designed to effectively treat patients with advanced solid tumors. Dr. Rosen rapidly developed a reputation for excellence in the conduct of gastrointestinal malignancy research and early stage clinical trials for patients with solid tumors. He has led pivotal clinical trials of many products subsequently approved by the United States Food and Drug Administration (FDA) for the treatment of cancer including Camptosar (irinotecan HCL injection), Eloxatin (oxaliplatin) and Zometa (zoledronic acid for injection) and Sutent. Dr. Rosen was featured on the CBS television program 60 Minutes in 2000 for his work on angiogenesis inhibitors (a new class of drugs developed to treat cancer by inhibiting development of new blood vessels). Dr. Rosen received his Medical Degree from Baylor College of Medicine in Houston, Texas, his B.A. in English Literature from Yale University and Masters of Public Policy (M.P.P.) from Harvard University's John F. Kennedy School of Government. In addition to conducting research, Dr. Rosen speaks widely on the subject of cancer and new therapies, is an educator, and consults with research sponsors in the design of clinical trials.
Alice B. Gottlieb, M.D., Ph.D.
Tufts New England Medical Center
Dr. Gottlieb is an internationally recognized expert and leader in the field of psoriasis and psoriatic arthritis. In March, 2006, she joined Tufts-New England Medical Center as its Chair of Dermatology and Dermatologist-in-Chief of the hospital, and as the Harvey B. Ansell Professor of Dermatology at Tufts University School of Medicine. She is the former Professor of Medicine and Founding Director of the Psoriasis Center of Excellence at UMDNJ-Robert Wood Johnson Medical School. Her research using targeted immunobiologics as pathogenic probes, provided new understanding of the pathogenesis of psoriasis and provided the foundation for biologic drug development in psoriasis and psoriatic arthritis. She has authored over 155 peer-reviewed articles. She has presented her research at more than 200 dermatology and rheumatology conferences in Europe, Asia and the United States, as well as at the FDA and the National Academy of Sciences. She is on almost every list of outstanding doctors, including Best Doctors in America and Best Doctors in Boston. She is triple boarded in dermatology, rheumatology and internal medicine, and is one of only a handful of doctors in the United States to be certified in all three of these specialties. Dr. Gottlieb has received numerous awards for mentoring and teaching including Honorary Membership in Alpha Omega Alpha in recognition of medical student teaching, a Research Mentorship award from the Internal Medicine house staff and a Mentorship Award from the American Chemical Society for mentoring minority high school students in bench and clinical research. Dr. Gottlieb is a member of the American Dermatological Association and Noah Worcester Dermatology Society amongst other professional societies.